{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T12:09:41Z","timestamp":1777550981027,"version":"3.51.4"},"reference-count":23,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1002\/jps.22016","type":"journal-article","created":{"date-parts":[[2009,12,3]],"date-time":"2009-12-03T19:32:43Z","timestamp":1259868763000},"page":"2664-2671","source":"Crossref","is-referenced-by-count":43,"title":["Pharmacokinetics and Disposition of a Localized Lymphatic Polymeric Hyaluronan Conjugate of Cisplatin in Rodents"],"prefix":"10.1016","volume":"99","author":[{"given":"Shuang","family":"Cai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumei","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neal M.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark S.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Laird Forrest","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1002\/jps.22016_bb0005","unstructured":"FDA oncology tools approval summary for cisplatin for metastatic ovarian tumors, 2008. Available from: http:\/\/www.accessdata.fda.gov\/scripts\/cder\/onctools\/summary.cfm?ID=73 [cited December 12, 2008]."},{"key":"10.1002\/jps.22016_bb0010","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s00280-008-0711-0","article-title":"Prevention of cisplatin nephrotoxicity: State of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care","volume":"61","author":"Launay-Vacher","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1002\/jps.22016_bb0015","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.clon.2005.06.010","article-title":"High efficacy of gemcitabine and cis-platin plus trastuzumab in patients with HER2-overexpressing metastatic breast cancer: A phase II study","volume":"17","author":"Stemmler","year":"2005","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1002\/jps.22016_bb0020","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/sj.ki.5002786","article-title":"Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies","volume":"73","author":"Pabla","year":"2008","journal-title":"Kidney Int"},{"key":"10.1002\/jps.22016_bb0025","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/ki.1984.86","article-title":"Uptake and metabolism of cisplatin by rat kidney","volume":"25","author":"Safirstein","year":"1984","journal-title":"Kidney Int"},{"key":"10.1002\/jps.22016_bb0030","first-page":"1564","article-title":"Chemotherapy with consecutive low-dose CDDP combined with 5-FU for gynecologic malignancies","volume":"26","author":"Shimizu","year":"1999","journal-title":"Gan To Kagaku Ryoho"},{"key":"10.1002\/jps.22016_bb0035","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.radonc.2008.06.003","article-title":"Hearing loss due to concurrent daily low-dose cisplatin chemoradiation for locally advanced head and neck cancer","volume":"89","author":"Zuur","year":"2008","journal-title":"Radiother Oncol"},{"key":"10.1002\/jps.22016_bb0040","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.soc.2008.04.004","article-title":"Percutaneous pelvic perfusion with extra- corporeal chemofiltration for advanced uterine cervical carcinoma","volume":"17","author":"Maruo","year":"2008","journal-title":"Surg Oncol Clin N Am"},{"key":"10.1002\/jps.22016_bb0045","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jss.2008.02.048","article-title":"Intralymphatic chemotherapy using a hyaluronan-cisplatin conjugate","volume":"147","author":"Cai","year":"2008","journal-title":"J Surg Res"},{"key":"10.1002\/jps.22016_bb0050","doi-asserted-by":"crossref","first-page":"12681276","DOI":"10.1002\/jps.21103","article-title":"Cisplatin-incorporated hyaluronic acid nanoparticles based on ion-complex formation","volume":"97","author":"Jeong","year":"2008","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.22016_bb0055","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s10585-005-0745-1","article-title":"A new model for lymphatic metastasis: Development of a variant of the MDA-MB-468 human breast cancer cell line that aggressively metastasizes to lymph nodes","volume":"22","author":"Vantyghem","year":"2005","journal-title":"Clin Exp Metastasis"},{"key":"10.1002\/jps.22016_bb0060","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/00001813-199304000-00006","article-title":"Antitumor activity of a new series of platinum complexes: Trans(+\/\u2212)-1,2-cyclohexanediammineplatinum(II) conjugated to acid polysaccharides","volume":"4","author":"Maeda","year":"1993","journal-title":"Anticancer Drugs"},{"key":"10.1002\/jps.22016_bb0065","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/mrm.10583","article-title":"Comparison of dendrimer-based macromolecular contrast agents for dynamic micro-magnetic resonance lymphangiography","volume":"50","author":"Kobayashi","year":"2003","journal-title":"Magn Reson Med"},{"key":"10.1002\/jps.22016_bb0070","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/bjs.1800720714","article-title":"Complications and hospital stay after surgery for breast cancer: A prospective study of 385 patients","volume":"72","author":"Tejler","year":"1985","journal-title":"Br J Surg"},{"key":"10.1002\/jps.22016_bb0075","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/0002-9610(91)90905-S","article-title":"Wound complications after modified radical mastectomy compared with tylectomy with axillary lymph node dissection","volume":"161","author":"Vinton","year":"1991","journal-title":"Am J Surg"},{"key":"10.1002\/jps.22016_bb0080","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/sj.bjc.6602772","article-title":"Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats","volume":"93","author":"Uchino","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1002\/jps.22016_bb0085","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1158\/1078-0432.CCR-03-0315","article-title":"A phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors","volume":"10","author":"Rademaker-Lakhai","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1002\/jps.22016_bb0090","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0168-3659(99)00248-5","article-title":"Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review","volume":"65","author":"Maeda","year":"2000","journal-title":"J Control Release"},{"key":"10.1002\/jps.22016_bb0095","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ijpharm.2008.03.025","article-title":"Determinants for in vivo anti-tumor effects of PEG liposomal doxorubicin: Importance of vascular permeability within tumors","volume":"359","author":"Ogawara","year":"2008","journal-title":"Int J Pharm"},{"key":"10.1002\/jps.22016_bb0100","first-page":"41","article-title":"Turnover and metabolism of hyaluronan","volume":"143","author":"Fraser","year":"1989","journal-title":"Ciba Found Symp"},{"key":"10.1002\/jps.22016_bb0105","first-page":"3935","article-title":"Block copolymer carrier systems for translymphatic chemotherapy of lymph node metas- tases","volume":"27","author":"D\u00fcnne","year":"2007","journal-title":"Anticancer Res"},{"key":"10.1002\/jps.22016_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.ASN.0000042803.28024.92","article-title":"Metabolism of cisplatin to a nephrotoxin in proximal tubule cells. I","volume":"14","author":"Townsend","year":"2003","journal-title":"Am Soc Nephrol"},{"key":"10.1002\/jps.22016_bb0115","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1248\/bpb.28.1954","article-title":"Continuous exposure to low-dose cisplatin and apoptosis","volume":"28","author":"Kishimoto","year":"2005","journal-title":"Biol Pharm Bull"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354915325910?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354915325910?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T06:36:49Z","timestamp":1558679809000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354915325910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["S0022354915325910"],"URL":"https:\/\/doi.org\/10.1002\/jps.22016","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}